Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis
Journal of Clinical Investigation · 15.06.2026 · 136 (12)
DOI: 10.1172/jci198031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 07.05.2026. Verfasst von Xuexi Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Idiopathic Pulmonary Fibrosis, Cytokines, Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Alveolar type 2 (AT2) progenitor cell exhaustion and impaired regenerative capacity are key pathogenic hallmarks in idiopathic pulmonary fibrosis (IPF). Nicotinamide adenine dinucleotide (NAD + ) functions as a central regulator of cellular energy metabolism. We have previously reported that downregulation of NAD + -dependent sirtuin signaling contributes to the impaired progenitor cell function of IPF AT2 cells. In this study, we found that a key NAD + biosynthesis enzyme, nicotinamide phosphoribosyltransferase (NAMPT), was significantly downregulated in IPF AT2 cells. NAMPT deficiency impaired AT2 renewal and enhanced lung fibrosis through downregulation of SIRT7 and SOD2, which resulted in increased oxidative stress, mitochondrial dysfunction, accumulated aberrant transitional cells, and impaired differentiation from AT2 to alveolar type 1 (AT1) cells. A mouse model with AT2-specific deletion of Nampt showed severely impaired AT2 renewal capacity and increased susceptibility to bleomycin lung injury. Activation of NAMPT by small-molecule activators promoted IPF AT2 renewal and reversed lung fibrosis in WT mice. NAMPT activation is a potentially promising therapeutic strategy for restoring AT2 progenitor cell function and halting or reversing progressive pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Department of Nutritional Science and Toxicology, University of California, Berkeley, California, USA.
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Advent Health Translational Research Institute, Orlando, Florida, USA.
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Förderung
- NIA NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
- American Heart Association
- Pulmonary Fibrosis Foundation
Zitieren
APA
Zhang, X., Liu, X., Qiao, Y., Rabata, A., Liu, N., Yao, C., Parimon, T., Chen, D., Hogaboam, C., Chen, P., Stripp, B., Gardell, S. J., Jiang, D., Noble, P. W., & Liang, J. (2026). Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 136(12). https://doi.org/10.1172/jci198031
Vancouver
Zhang X, Liu X, Qiao Y, Rabata A, Liu N, Yao C, et al. Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis. Journal of Clinical Investigation. 2026;136(12). doi:10.1172/jci198031
BibTeX
@article{Zhang2026,
author = {Zhang, Xuexi and Liu, Xue and Qiao, Yujie and Rabata, Anas and Liu, Ningshan and Yao, Changfu and Parimon, Tanyalak and Chen, Danica and Hogaboam, Cory and Chen, Peter and Stripp, Barry and Gardell, Stephen J and Jiang, Dianhua and Noble, Paul W and Liang, Jiurong},
title = {Activation of the impaired NAMPT/SIRT7/SOD2 axis restores alveolar progenitor cell renewal in idiopathic pulmonary fibrosis},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {12},
doi = {10.1172/jci198031}
}
EUVIMED